



Psychedelic Inspired Medicines

NEO: MMED

Corporate Presentation

March 2020

[MindMed.co](https://www.MindMed.co)

Disclaimer

Market and Industry Data

This presentation by Mind Medicine (MindMed) Inc. (the “Presentation”) includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

CAUTIONARY NOTE ON FORWARD LOOKING INFORMATION

This Presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking information”) with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approval, the likelihood of obtaining patents or the efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: MindMed’s ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed not electing to proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful.

To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed’s financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future.

Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking Information in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein.

A Paradigm Shift Is Needed In Mental Health

Psychedelic Inspired Medicines offer solutions to retool & address a continuum of large mental health problems.

Anxiety

40m¹

U.S. Adults affected by anxiety

ADHD

10m²

U.S. Adults use stimulant
prescription medicines.

Addiction

20m³

Americans w/ Substance
Abuse Disorders


Depression

17m⁴

Adults with major depression

A Psychedelic Opportunity

Through regulated human clinical trials, MindMed develops medicines inspired by psychedelics that address significant unmet needs.



A New Class of Medicines

MindMed is pioneering a new way to treat mental health

Psychedelic Inspired Medicines

Non-Hallucinogenic Medicines



Derived from psychedelics, zero to negligible hallucination effect



Doctor prescription



Pharmacy pickup, take-home

Examples:




Microdose LSD & Psilocybin
18-MC



Hallucinogenic Therapies



A high dose or experiential dose of psychedelics



Direct supervision and therapy session overseen by therapist & doctor



In-clinic treatment only



Examples:

Esketamine
(J&J Approved in 2019) *Psilocybin, LSD, MDMA*

MindMed's Regulatory Approach

Psychedelics Will Be Commercialized As Regulated Medicines

- ✓ Regulated Clinical Trials of Schedule 1 Substances are Legal.

High Barriers to Entry & Limiting Factors

- GMP Production & Supply of Drugs
- Research Scientists with Psychedelics Background
- Experienced Clinical Drug Development Teams
- Clinical Data Licensing
- Development of IP/ Patent Filings
- Pre-Clinical, Phase I,2,3 trials cost time & \$\$\$

- ✓ Regulatory Approvals/Federal Regulation Enable Market Exclusivity
- ✓ IP Defendability= Institutional Capital

- ✓ First FDA approved psychedelic medicine in March 2019 established precedent

SPRAVATO (esketamine)

Approved Psychedelic by FDA
(Treatment Resistant Depression)

Spravato[™]
(esketamine) 
nasal spray



Annual Global Sales Forecast in 2024

~\$1.3 Billion USD⁵

~\$1.7 Billion CAD

Clinical Pipeline

MindMed is advancing and building a compelling pipeline of psychedelic inspired medicines through clinical trials.

MindMed will continue to expand its pipeline & IP over the next 6-12 months through

- Co-Development Agreements
- In-Licensing with leading academic research institutions of. existing & new clinical research in psychedelics
- Proprietary clinical trials with new psychedelics

Non-hallucinogenic psychedelics	Area of research	Pre-clinical	Phase 1	Phase 1B	Phase 2	Phase 3	Next anticipated milestone
18-MC (Ibogaine Derivative)	Opioid Withdrawal Treatment	→					2020: Phase 2 initiation
	Opioid Use Disorder (OUD)	→					2021: Phase 3 initiation
Microdose LSD	Adult ADHD	→					2020: Phase 2 initiation




Opioid Crisis Calls for Urgent Solution

Existing Addiction Treatments Are Inadequate

"If we're just substituting one opioid for another,
we're not moving the dial much"

- Tom Price, former U.S. Secretary of HHS



Example: Suboxone >90% Failure Rate

New FDA Incentives for Opioid Treatments

April 2018

Accelerated Approval/Breakthrough
Designation for development of treatments
for opioid use disorders.

Lowered threshold for approval (August 2018)

Lower threshold for approval:
"fewer occasions per day" rather than
total abstinence.

18-MC: A Solution For The Opioid Crisis

A transformational approach to addiction based on the psychedelic substance Ibogaine.

Ibogaine (psychedelic substance)

✓ Highly Effective Addiction Treatment

Downsides

✗ Cardiac Toxicity Risk

✗ Long Hallucinogenic Experience

✗ Schedule 1



18-MC: Safer than Ibogaine (psychedelic substance)

✓ Highly Effective Addiction Treatment

Upsides

✓ Cardiac Safe




✓ Non Hallucinogenic

✓ Not a Schedule 1 Substance

18-MC: A Solution For The Opioid Crisis (cont.)


Reducing Addictive Substances Without The Trip

Positive Dose Response proved that the higher the dose of 18-MC, the less opiates are consumed.




"A derivative of ibogaine with similar effects on withdrawal and craving, but without the cardiotoxicity or strange visions."

WIRED



18-MC Addresses Addiction As A Brain Disease

Addiction is a disease of the brain: All addictive substances result in dysregulation of the dopamine reward pathway




Brain images showing decreased dopamine receptors in the brain of a person addicted to cocaine versus a non-drug user.

Key Insight: New addiction solutions must address dopamine dysregulation in patients.

18-MC Addresses Addiction As A Brain Disease (cont.)

Opioid addiction alters the brain to crave and release more dopamine which creates a 'high'.



Key Insight: New addiction solutions must address dopamine dysregulation in patients.

A Disruptive Solution For Addiction Will Be Highly Valuable

Treatments that are not highly effective
still generate huge annual revenues

Projected Worldwide Pharma
Sales for Opioid Abuse in 2019

\$2.9 Billion⁹

Blockbuster Drug Potential (other indications)

Substance Abuse by the Numbers¹⁰

- Opioid use disorder 2 m
- Alcohol use disorder 14.8 m
- Tobacco users 47 m
- Cocaine use disorder 1 m
- Methamphetamine use disorder 1 m

\$42 Billion¹¹

(US Addiction Rehab Market)

Addressable Market

Microdosing Program

MindMed is conducting first ever Phase 2 Microdosing Trial in Adult ADHD

10 Million ADHD adult sufferers
(~4.4% of 18+ population)¹²


16 Million US Adults On Prescription Stimulants¹³

Abuse deterrent formulations IP

MindMed is developing IP that enables LSD, Psilocybin microdoses to be taken home

FDA clinical trials

MindMed will conduct FDA clinical trials performed with rigorous science enabling clear regulatory pathway



Microdosing

Illegal Recreational / Non-Clinical Trend

Widespread usage in Silicon Valley: Millennials seek ways to get off ADHD stimulants meds: Ritalin, Adderall

- ⊗ Illegal & self-prescribed usage
- ⊗ No medical supervision or supporting clinical data

Non-Hallucinogenic Medicines

Potential Approved Medicines

LSD Micro

Psilocybin Micro

Rx Doctor prescriptions

🏠 Pharmacy pickup, take-home

ADHD Demographics & Market In the U.S.

People with ADHD are at least

1.5-times¹⁴

more likely to develop substance abuse disorders to substances like nicotine, alcohol, marijuana, and cocaine.


10.9%¹⁵

of adults with ADHD receive treatment

Only

25%¹⁶

of adults with ADHD had been diagnosed in childhood or adolescence.



ADHD diagnoses **among adults** are growing **four times faster** than diagnoses among children in the United States. The **prevalence of ADHD among adults** rose from 0.43% to 0.96% **between 2007 and 2016** a 123% increase¹⁷

123%

ADHD Market Dominated by Stimulants

- Amphetamine/dextroamphetamine mixed salts (Adderall)
- Amphetamine/dextroamphetamine mixed salts extended release (Adderall XR)
- Dexmethylphenidate extended release (Focalin)
- Dexmethylphenidate sulfate extended release (Zenzedi)
- Dexmethylphenidate sulfate extended release (Dexedrine Spansule)
- Lisdexamfetamine (Vyvanse)
- Methylphenidate (Aptensio XR, Concerta, Daytrana, Metadate CD, Metadate ER, Ritalin, Ritalin-SR, Methylin, Ritalin LA, Quillivant XR)

Projected Worldwide Pharma Sales
for ADHD in 2019

\$9.2 Billion¹⁸

MindMed in The News

Investing.com

"Next big space in the pharmaceutical sector – next-generation psychedelic-inspired medicines."

BUSINESS INSIDER

"A startup that wants to use psychedelics to treat addiction just raised \$6.2 million from the host of Shark Tank and the architect behind the world's biggest cannabis grower"

FORTUNE

Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution. February 17, 2020

THE WALL STREET JOURNAL.

Psychedelics-Drug Startup Raises \$24 Million Ahead of IPO . February 27, 2020

Forbes

"...Huge advantage in the company's favor is that the drug (18MC) is not classified under the Controlled Substance Act. But perhaps the most compelling case for the company is the real and pressing need for an effective anti-addiction solution in a country ravaged by the opioid crisis."

FAST COMPANY

"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?"
-Kevin O' Leary

Bloomberg

Move Over, Pot: Psychedelic Companies Are About to Go Public. Mind Medicine plans to list on Toronto's NEO Exchange in March



36 STARTUPS
that could change
the world




MindMed named one of 36 startups that could change the world

Potential Catalysts

Critical Milestones Accelerating Over Next 12 Months

← Past Execution

- ✓ Activated Addiction Medicine Program
 - ✓ Established Microdosing Program
 - ✓ Executed LOI for ADHD LSD Microdosing program
 - ✓ Secured GMP Supply of LSD ready in Q3 2019
 - ✓ Announced Definitive Arrangement for RTO (Oct 2019)
- Phase 1 MAD & Phase 1 SAD IRB Approval in Australia



12 Month Milestones & Catalysts →

- ★ 18-MC in Addiction Medicine: Complete Phase 1B (2020)
- ★ Phase 2 Opioid Withdrawal first patient enrolled (2020)
- ★ Microdose LSD in ADHD: Phase 2 first patient enrolled (2020)

Corporate Development:

Announce additional psychedelic program LOIs / Definitive Agreements with Neurology and Psychiatry programs
Announce further clinical trials pipeline additions

Investment

Significant Past Investment in 18-MC

\$14.6M CAD
Invested in 18-MC

MindMed acquired
18-MC Addiction Program
September, 2019

\$9M CAD
Grant by NIDA 2013

\$9.2M CAD
MindMed Seed Round
August 2019

New Capital To Execute

\$32M CAD
Pre-Public Financing Complete
February 2020

Public Listing
on NEO Exchange:
MMED




Investors in MindMed



"Through psychedelic inspired medicines, MindMed has the potential to treat the most challenging and damaging mental health issues of our time."

- James Bailey, Bail Capital
MindMed Investor

Bruce Linton Joined MindMed as strategic investor & board member



"There's probably untapped value, which will only go to the people who are at the beginning and bold"

"foresees a "similar run" for psychedelics as cannabis, but doesn't propose that they also become social or recreational products."

Sep 19, 2019

Kevin O'Leary:



"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?"

Dec. 9, 2019 for Fast Company

Executive Team



JR Rahn,
Founder & Co-CEO



Stephen L. Hurst, JD
Founder & Co-CEO



Donald Gehlert, PhD
Chief Scientific Officer



Carol Nast,
Chief Operating Officer



Scott Freeman, MD.
Chief Medical Officer
and President



Jeanne Bonelle
EVP, Global Quality



Paul Van Damme
Chief Financial Officer



Pre-Public Valuation (Feb 2020):

\$0.33 CAD / Share

\$83 M CAD

Outstanding Shares :

255,431,251

LISTED ON
NEO



Board of Directors/ Scientific Advisory Board



Bruce Linton
Director



JR Rahn,
Co-CEO & Director



Stephen L. Hurst, JD
Co-CEO & Exec Chairman



Brigid Makes
Director



Perry Dellelce,
Director



Stanley D. Glick, PhD, MD
Inventor 18-MC, Chair of
Scientific Advisory Board



Stanley D. Glick, PhD, MD
Inventor 18-MC, Chair of
SAB & Senior Clinical Advisor



John Rotrosen, MD



Kenneth Alper, MD



Sarah McCallum, PhD



Jed Rose, PhD



John Blacker, PhD



Natalie Wheeler, PhD



Eric Edwards, MD, PhD



Sources

1. Anxiety and Depression Association of America, Facts & Statistics,
2. Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD),
3. SAMSA, Results from the 2018 National Survey on Drug Use and Health,
4. The National Institute of Mental Health, Prevalence of Major Depressive Episode Among Adults
5. EvaluatePharma Outlook for Depression Drugs, 2/13/2019
6. The Council of Economic Advisers (CEA), The Underestimated Cost of the Opioid Crisis, November 2017
7. SAMSA, Results from the 2018 National Survey on Drug Use and Health,
8. Center for Disease Control and Prevention. NCS Data Brief 293, <https://www.hhs.gov/opioids/about-the-epidemic/index.html> ; <https://www.cdc.gov/drugoverdose/data/statedeaths.html>
9. IMS Opioid Abuse sDisease Value, IMS Health
- 10.SAMSA, Results from the 2018 National Survey on Drug Use and Health
11. Addiction Rehab Industry: Market Research Report, January 2020, Marketdata Enterprises, Inc.
- 12.The National Institute of Mental Health Information Resource Center, Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the U.S.
- 13.Wilson M. Compton, M.D., M.P.E., Beth Han, M.D., Ph.D., M.P.H., Carlos Blanco, M.D., Ph.D., Kimberly Johnson, PhD., and Christopher M. Jones, Pharm.D., M.P.H., Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the U.S., Am J Psychiatry. 2018 August 01; 175(8): 741–755. doi:10.1176/appi.ajp.2018.17091048
- 14.Lee, Steve S et al. (2011). Prospective Association of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) and Substance Use and Abuse/Dependence: A Meta-Analytic Review. Clinical Psychology Review. Vol. 31,3: 328–41. doi:10.1016/j.cpr.2011.01.006. Retrieved from: <https://www.sciencedirect.com/science/article/pii/S0272735811000110?via%3Dihub>
- 15.Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Zaslavsky, A. M. (2006). The Prevalence and Correlates of Adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry. 163, 716–723. doi:10.1176/appi.ajp.163.4.716. Retrieved from: https://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.4.716?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
- 16.Faraone SV, Spencer TJ, Montano CB, Biederman J. (2004). Attention-Deficit/Hyperactivity Disorder in Adults: A Survey of Current Practice in Psychiatry and Primary Care. Arch Intern Med.164(11):1221–1226. doi:10.1001/archinte.164.11.1221. Retrieved from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/217065>,
17. Chung W, Jiang S, Paksarian D, et al. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups. JAMA Netw Open. 2019;2(11):e1914344. doi:<https://doi.org/10.1001/jamanetworkopen.2019.14344>
- 18.IMS ADHD Disease Value, IMS Health



Thank you

invest@mindmed.co

Corporate Presentation
www.mindmed.co